Samarth Kulkarni - Jul 27, 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Jul 27, 2022
Transactions value $
-$1,522,829
Form type
4
Date filed
7/29/2022, 05:38 PM
Previous filing
Jul 5, 2022
Next filing
Aug 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise $105K +8.33K +2.87% $12.57 299K Jul 27, 2022 Direct
transaction CRSP Common Shares Options Exercise $270K +16.7K +5.58% $16.21 315K Jul 27, 2022 Direct
transaction CRSP Common Shares Sale -$524K -6.93K -2.2% $75.64 308K Jul 27, 2022 Direct F1, F2
transaction CRSP Common Shares Sale -$53.5K -700 -0.23% $76.37 308K Jul 27, 2022 Direct F1, F3
transaction CRSP Common Shares Sale -$54.5K -700 -0.23% $77.79 307K Jul 27, 2022 Direct F1, F4
transaction CRSP Common Shares Sale -$966K -12.8K -4.16% $75.73 294K Jul 27, 2022 Direct F1, F5
transaction CRSP Common Shares Sale -$252K -3.31K -1.12% $76.29 291K Jul 27, 2022 Direct F1, F6
transaction CRSP Common Shares Sale -$46.8K -600 -0.21% $77.97 290K Jul 27, 2022 Direct F1, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Options Exercise $0 -8.33K -100% $0.00* 0 Jul 27, 2022 Common Shares 8.33K $12.57 Direct F8
transaction CRSP Stock Option (Right to Buy) Options Exercise $0 -16.7K -16.67% $0.00 83.3K Jul 27, 2022 Common Shares 16.7K $16.21 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.06 to $76.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.06 to $76.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.345 to $77.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.15 to $76.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.16 to $76.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.97 to $77.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F8 This option was granted on July 15, 2016 with respect to 93,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.
F9 This option was granted on May 3, 2017 with respect to 100,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning May 31, 2017.